Eupraxia Pharmaceuticals Inc (EPRX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 12-2023 | 09-2023 | 06-2023 | 03-2023 | 12-2022 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -28,966 | -18,359 | -13,463 | -3,956 | -18,991 |
| Depreciation Amortization | 156 | 114 | 76 | 38 | 148 |
| Accounts receivable | -104 | 21 | 38 | 2 | N/A |
| Other Working Capital | 5,352 | -164 | -448 | -1,419 | 1,515 |
| Other Operating Activity | 2,878 | 3,604 | 4,957 | 769 | 2,933 |
| Operating Cash Flow | $-20,684 | $-14,784 | $-8,839 | $-4,567 | $-14,395 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -73 | -24 | -14 | -8 | -235 |
| Other Investing Activity | 0 | 0 | 0 | 0 | 10,069 |
| Investing Cash Flow | $-73 | $-24 | $-14 | $-8 | $9,834 |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | 5,272 | 5,246 | 4,825 | 230 | N/A |
| Other Financing Activity | 15,742 | 15,827 | -39 | -36 | 10,801 |
| Financing Cash Flow | $21,014 | $21,073 | $4,786 | $195 | $10,801 |
| Exchange Rate Effect | 821 | 35 | 228 | 45 | -507 |
| Beginning Cash Position | 18,263 | 18,263 | 18,263 | 18,263 | 12,531 |
| End Cash Position | 19,342 | 24,564 | 14,423 | 13,928 | 18,263 |
| Net Cash Flow | $1,078 | $6,300 | $-3,841 | $-4,336 | $5,733 |
| Free Cash Flow | |||||
| Operating Cash Flow | -20,684 | -14,784 | -8,839 | -4,567 | -14,395 |
| Capital Expenditure | -73 | -24 | -14 | -8 | N/A |
| Free Cash Flow | -20,757 | -14,808 | -8,854 | -4,575 | -14,395 |